The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte MARSHALL D. CREW,
DWAYNE T. FRIESEN,
BRUNO C. HANCOCK, CHRIS MACRI
JAMES A.S. NIGHTINGALE, and
RAVI M. SHANKER
__________
Appeal No. 2006-3379
Application No. 10/393,549
__________
ON BRIEF
__________
Before MILLS, GREEN, and LEBOVITZ, Administrative Patent Judges.
LEBOVITZ, Administrative Patent Judge.
DECISION ON APPEAL
This appeal involves claims to process for forming a pharmaceutical composition
containing amorphous dispersion particles. The Examiner has rejected the claims as
anticipated and obvious. We have jurisdiction under 35 U.S.C. § 134. We affirm-in-
part.
Background
“Type 2 diabetes is often treated by drugs designed to suppress hepatic glucose
production.” Specification, page 1, lines 5-6. A particularly effective drug is
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007